Mycosis fungoides primary prevention: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Cutaneous T cell lymphoma}} | {{Cutaneous T cell lymphoma}} | ||
{{CMG}} | {{CMG}}; {{AE}} | ||
==Overview== | ==Overview== | ||
There are no established measures for the primary prevention of [disease name]. | |||
OR | |||
There are no available vaccines against [disease name]. | |||
OR | |||
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3]. | |||
OR | |||
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3]. | |||
==Primary Prevention== | |||
There are no established measures for the primary prevention of [disease name]. | |||
OR | |||
There are no available vaccines against [disease name]. | |||
OR | |||
Effective measures for the primary prevention of [disease name] include: | |||
*[Measure1] | |||
*[Measure2] | |||
*[Measure3] | |||
OR | |||
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include: | |||
*[Strategy 1] | |||
*[Strategy 2] | |||
*[Strategy 3] | |||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
{{ | {{WH}} | ||
{{ | {{WS}} |
Revision as of 15:10, 30 October 2018
Cutaneous T cell lymphoma Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the primary prevention of [disease name].
OR
There are no available vaccines against [disease name].
OR
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
Primary Prevention
There are no established measures for the primary prevention of [disease name].
OR
There are no available vaccines against [disease name].
OR
Effective measures for the primary prevention of [disease name] include:
- [Measure1]
- [Measure2]
- [Measure3]
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]